<DOC>
	<DOC>NCT01418222</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.</brief_summary>
	<brief_title>FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in patients with metastatic (Stage IV) disease Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Measurable disease by RECIST criteria Adequate organ system function, as defined by protocol Prior systemic or radiation therapy for metastatic colorectal cancer Adjuvant chemotherapy (and/or chemoradiation) for colorectal cancer within 12 months prior to date of diagnosis of metastatic disease Previously untreated brain metastases History of hypersensitivity to active or inactive excipients of any component of treatment, or known dipyrimidine dehydrogenase deficiency Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) History of hematemesis or hemoptysis &lt;/= 1 months prior to study enrollment Significant cardiovascular disease or disorder History of abdominal fistula or gastrointestinal perforation &lt;/= 6 months prior to Day 1 Positive for hepatitis B, hepatitis C or HIV infection Other active cancers or history of treatment for invasive cancer within the last 5 years, except for nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>